BACKGROUND: Serum amyloid P component (SAP) and acute phase proteins like C-reactive protein contribute to the clearance of apoptotic cells. This response is diminished in systemic lupus erythematosus (SLE). OBJECTIVES: To analyse SAP concentrations in SLE in relation to disease activity, and investigate whether SAP reacts like an acute phase protein. METHODS: SAP was measured in 40 patients with SLE during active and inactive disease and compared with healthy controls and patients with rheumatoid arthritis and Wegener's granulomatosis. Normal SAP values were determined in 120 healthy controls by ELISA. C reactive protein and serum amyloid A (SAA) were measured in all subjects and their levels related to SAP. SAP was also measured serially in 11 patients with breast cancer treated with recombinant human interleukin-6, and in 16 patients with sepsis. RESULTS: In SLE, SAP was unaltered compared with healthy controls and was not influenced by disease activity, in contrast to C reactive protein and SAA, which increased during active disease. SAP increased in Wegener's granulomatosis but not in rheumatoid arthritis. The rise in C reactive protein and SAA was most pronounced in Wegener's granulomatosis with active disease. SAP did not change significantly during an acute phase response. No correlation was found between SAP and C reactive protein or SAA, but there was a correlation between SAA and C reactive protein (r = 0.4989, p = 0.0492). CONCLUSIONS: Patients with SLE have normal circulating SAP levels. In contrast to C reactive protein or SAA, SAP does not act as an acute phase protein.
BACKGROUND:Serum amyloid P component (SAP) and acute phase proteins like C-reactive protein contribute to the clearance of apoptotic cells. This response is diminished in systemic lupus erythematosus (SLE). OBJECTIVES: To analyse SAP concentrations in SLE in relation to disease activity, and investigate whether SAP reacts like an acute phase protein. METHODS:SAP was measured in 40 patients with SLE during active and inactive disease and compared with healthy controls and patients with rheumatoid arthritis and Wegener's granulomatosis. Normal SAP values were determined in 120 healthy controls by ELISA. C reactive protein and serum amyloid A (SAA) were measured in all subjects and their levels related to SAP. SAP was also measured serially in 11 patients with breast cancer treated with recombinant humaninterleukin-6, and in 16 patients with sepsis. RESULTS: In SLE, SAP was unaltered compared with healthy controls and was not influenced by disease activity, in contrast to C reactive protein and SAA, which increased during active disease. SAP increased in Wegener's granulomatosis but not in rheumatoid arthritis. The rise in C reactive protein and SAA was most pronounced in Wegener's granulomatosis with active disease. SAP did not change significantly during an acute phase response. No correlation was found between SAP and C reactive protein or SAA, but there was a correlation between SAA and C reactive protein (r = 0.4989, p = 0.0492). CONCLUSIONS:Patients with SLE have normal circulating SAP levels. In contrast to C reactive protein or SAA, SAP does not act as an acute phase protein.
Authors: R Y Leavitt; A S Fauci; D A Bloch; B A Michel; G G Hunder; W P Arend; L H Calabrese; J F Fries; J T Lie; R W Lightfoot Journal: Arthritis Rheum Date: 1990-08
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: J W Tervaert; M G Huitema; R J Hené; W J Sluiter; T H The; G K van der Hem; C G Kallenberg Journal: Lancet Date: 1990-09-22 Impact factor: 79.321
Authors: Ana P Castaño; Shuei-Liong Lin; Teresa Surowy; Brian T Nowlin; Swathi A Turlapati; Tejas Patel; Ajay Singh; Shawn Li; Mark L Lupher; Jeremy S Duffield Journal: Sci Transl Med Date: 2009-11-04 Impact factor: 17.956
Authors: G Zandman-Goddard; M Blank; P Langevitz; L Slutsky; M Pras; Y Levy; O Shovman; T Witte; A Doria; J Rovensky; Y Shoenfeld Journal: Ann Rheum Dis Date: 2005-07-13 Impact factor: 19.103
Authors: Hongtao Wang; James P Malone; Petra Erdmann Gilmore; Alan E Davis; John C Magee; R Reid Townsend; Robert O Heuckeroth Journal: J Pediatr Gastroenterol Nutr Date: 2010-04 Impact factor: 2.839
Authors: Richard H Gomer; Darrell Pilling; Lawrence M Kauvar; Stote Ellsworth; Sanna D Ronkainen; David Roife; Stephen C Davis Journal: Wound Repair Regen Date: 2009 May-Jun Impact factor: 3.617
Authors: Jun Xu; Min Cong; Tae Jun Park; David Scholten; David A Brenner; Tatiana Kisseleva Journal: Hepatobiliary Surg Nutr Date: 2015-02 Impact factor: 7.293
Authors: Debi K Swertfeger; Sandra Rebholz; Hailong Li; Amy S Shah; William Sean Davidson; Long J Lu Journal: J Clin Lipidol Date: 2018-08-27 Impact factor: 4.766